摘要
目的探讨重组人血管内皮抑制素联合放化疗对晚期头颈部鳞癌患者生存质量的影响。方法选取我院2016年1月至2018年1月收治的86例晚期头颈部鳞癌患者作为研究对象,按照治疗方式不同将其分为观察组(43例,重组人血管内皮抑制素联合放化疗)和对照组(43例,常规放化疗)。比较两组的疾病控制情况、急性不良反应发生情况、生存质量、希望水平及心理弹性。结果观察组的疾病控制率及缓解率均明显高于对照组(P<0.05)。两组各项急性不良反应发生情况基本相似(P>0.05)。治疗后,观察组的生存质量、HHI、CD-RISC评分均明显高于对照组(P<0.05)。结论重组人血管内皮抑制素联合放化疗能提高晚期头颈部鳞癌患者的疾病控制率及缓解率,改善患者的生存质量。
Objective To investigate the effect of recombinant human endostatin combined with chemoradiotherapy on quality of life in patients with advanced head and neck squamous cell carcinoma.Methods A total of 86 patients with advanced head and neck squamous cell carcinoma admitted in our hospital from January 2016 to January 2018 were selected as the research objects,and the patients were divided into observation group(43 cases,recombinant human endostatin combined with chemoradiotherapy)and control group(43 cases,conventional chemoradiotherapy)according to the different treatment methods.The disease control status,acute adverse reactions,quality of life,hope level and psychological resilience were compared between the two groups.Results The disease control rate and remission rate of the observation group were significantly higher than those of the control group(P<0.05).The occurrence of various acute adverse reactions in the two groups was basically similar(P>0.05).After treatment,the quality of life,HHI and CD-RISC scores of the observation group were significantly higher than those of the control group(P<0.05).Conclusion Recombinant human endostatin combined with chemoradiotherapy can improve the disease control rate and remission rate of patients with advanced head and neck squamous cell carcinoma,and improve the quality of life of patients.
作者
李志强
陈静
LI Zhiqiang;CHEN Jing(Baoji Central Hospital,Baoji 721000,China)
出处
《临床医学研究与实践》
2021年第12期33-35,共3页
Clinical Research and Practice
关键词
重组人血管内皮抑制素
头颈部鳞癌
放化疗
recombinant human endostatin
head and neck squamous cell carcinoma
chemoradiotherapy
